Latin America Molecular Diagnostics Market (2025-2032)
The Latin America Molecular Diagnostics Market was valued at $1.55 billion in 2024. This market is expected to reach $2.5 billion by 2032, from an estimated $1.64 billion in 2025, at a CAGR of 6.3% during the forecast period 2025-2032.
- Published
- Jan 2025
- Pages
- 220
- Format
- PDF + Excel
- Report ID
- MRHC - 1041076
- Base year
- 2025
- 2024 · HISTORICAL
- $1.55B
- 2032
- $2.50B
- CAGR 2025–2032
- 6.3%
2024 baseline · 2025–2032 forecast at 6.3% CAGR · hover a bar for the value
Key highlights
The Reagents & Kits Segment is Expected to Account for the Largest Share of the Market in 2025
The Laboratory Tests Segment is Expected to Account for the Largest Share of the Market in 2025
The Polymerase Chain Reaction (PCR) Segment is Expected to Account for the Largest Share of the Market in 2025
The Infectious Disease Segment is Expected to Account for the Largest Share of the Market in 2025
The Hospitals & Clinics Segment is Expected to Account for the Largest Share of the Market in 2025
Report summary
| Particulars | Details |
|---|---|
| Page No | ~220 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2025 |
| CAGR | 6.3% |
| Market Size (Value) | $2.50 billion |
| Market Size (Volume) | NA |
| Segments Covered | By Offering · Kits & Reagents · Instruments · Software & Services · By Test Type · Laboratory Tests · Point-of-Care (POC) Tests · By Technology · Polymerase Chain Reaction (PCR) · In Situ Hybridization (ISH) · Isothermal Nucleic Acid Amplification Technology (INAAT) · Microarrays · Sequencing · Mass Spectrometry · Other Technologies · (Note:Other technologies primarily include electrophoresis, southern blotting, northern blotting, and ligase chain reaction (LCR)) · By Application · Infectious Diseases · Respiratory Diseases · Hepatitis · HIV · Chlamydia Trachomatis/Neisseria Gonorrhoeae · Human Papillomavirus (HPV) · Healthcare-Associated Infections (HAIs) · Other Infectious Diseases · (Note:Other technologies primarily include meningococcal disease, norovirus (stomach flu), tropical diseases, hand, foot, and mouth disease (HFMD), and pertussis) · Oncology · Breast Cancer · Colorectal Cancer · Lung Cancer · Prostate Cancer · Lymphoma · Leukemia · Cervical Cancer · Other Cancer Types · Genetic Testing · Neurological Diseases · Cardiovascular Diseases · Other Applications · (Note:Other applications primarily include pharmacogenomics, forensic testing, environmental studies, educational study purposes, human & microorganism genomic research studies, and food & beverages testing) · By End User · Hospitals & Clinics · Diagnostic Laboratories · Academic & Research Institutes · Other End Users |
| Countries Covered | Latin America (Brazil, Mexico, Colombia, Argentina, Chile, Peru, Uruguay, and Rest of Latin America) |
| Key Companies | Bio-Manguinhos (Brazil), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Hologic, Inc. (U.S.), Illumina, Inc. (U.S.), OmicronLab (Mexico), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), Agilent Technologies, Inc. (U.S.). |
Report overview
Segments covered: offering, test type, technology, application, end user. Regions: Latin America.
Molecular diagnostics help detect the targeted genetic material in human, viral, and bacterial genomes. Molecular diagnostic tests are increasingly being used in many areas, including infectious diseases, oncology, and clinical genetics. Advancements in molecular diagnostics will continue to improve the accuracy and speed of diagnosis and will become an essential aspect of patient-tailored interventions and therapeutics.
The growth of the Latin America molecular diagnostics market is driven by several factors, including the rising global geriatric population, increasing prevalence of communicable & noncommunicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures. Factors such as growing scope in emerging economies, increasing focus on companion diagnostics, and rising popularity of direct-to-consumer (DTC) genetic testing are a few of the opportunities that would help grow the market in the future. A shortage of skilled professionals could be considered a challenge for the Latin America molecular diagnostics market. However, unfavorable regulatory frameworks and high costs of molecular diagnostic tests restrain the growth of the market.
Report infographic
Market dynamics
1 factors across 1 forceIncreasing Focus on Companion Diagnostics
Companion molecular diagnostics measures the levels of proteins, genes, or specific mutations to reveal specific and effective therapies for an individual’s condition. Companion diagnostics (CDx) are a form of personalized, stratified, and precision medicine that individualizes a patient’s treatment. CDx has expanded from oncology drugs to multiple therapeutic areas, and the number of combinations has grown significantly over the years. Also, personalized medicine for infectious diseases helps to orient the molecular management of infections. Molecular microbiology offers technologies that can detect and identify microorganisms rapidly.
Determining the pharmacogenomic profiles of patients suffering from infectious diseases provides an additional assessment of the drug metabolizer phenotype and/or of the risk of potential adverse drug interactions. Personalized medicine is thus expected to help develop new therapies and new methods for disease detection.
Table of contents
13 chapters · 104 sections · 220 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Reagents & Kits | — |
| By Test Type | Laboratory Tests | — |
| By Technology | Polymerase Chain Reaction (PCR) | — |
| By Application | Infectious Disease | — |
| By End User | Hospitals & Clinics | — |
By Offering
- The reagents & kits segment is expected to account for the largest share of the market.
- Molecular diagnostic kits are widely used by healthcare professionals in hospitals, clinics, and diagnostic laboratories to diagnose and manage various communicable & non-communicable diseases.
- Recurrent use of assays & kits in the detection of various diseases through molecular diagnostics, rise in product approvals, and technological advancements in molecular techniques contribute to the large market share of this segment.
By Test Type
- The laboratory tests segment is expected to account for the largest share of the market.
- Lab tests are traditionally used in hospitals and diagnostic centers and are widely accepted.
- The sample is taken from the patient and sent to the laboratory for processing and testing, where the technicians conduct the processing and testing and create a report for the clinician.
- The laboratory testing approach for molecular diagnostics has many advantages over other approaches.
- It has higher accuracy and reliability when compared to point-of-care testing, owing to which the adoption of molecular diagnostics in the lab is more compared to PoC tests.
By Technology
- The polymerase chain reaction (PCR) segment is expected to account for the largest share of the molecular diagnostics market in Latin America.
- PCR allows rapid amplification of a specific segment of DNA.
- This technology is sensitive and thus helps in the diagnosis of diseases.
- It is effective for low-number targets and less expensive than other technologies, such as sequencing.
- Hence, the huge demand for PCR devices further contributes to the segment’s largest share.
By Application
- The infectious disease segment is expected to account for the largest share of the molecular diagnostics market in Latin America.
- Infectious diseases are transmissible or communicable illnesses that spread quickly in some areas and become epidemics.
- It is crucial to quickly diagnose initial infections and prevent further spread through in vitro diagnosis.
- The growing prevalence of infectious diseases, the rising funds for infectious disease diagnostic research activities, and the sudden emergence of a pandemic are the factors attributed to the large market share of this segment.
By End User
- The hospitals & clinics segment is expected to account for the largest share of the molecular diagnostics market in Latin America.
- Factors contributing to the segment’s share include increased hospitalizations due to various diseases, the rise in the geriatric population, and the high prevalence of healthcare-associated infections (HAIs).
Geographic analysis
Latin America
Largest shareIn 2025, Brazil is expected to dominate the Latin America molecular diagnostics market. Brazil has a high prevalence of infectious diseases such as hepatitis, dengue, malaria, chikungunya, and zika, which pose significant challenges to the public healthcare system. For this, the Brazilian Ministry of Health, in accordance with the WHO, has outlined a national strategy that aims to expand access to prevention, diagnosis, and treatment of hepatitis C to reduce new infections and mortality. This is expected to offer significant opportunities for the growth of molecular diagnostics in Brazil.
Competitive landscape
- Bio-Manguinhos · Brazil
- F. Hoffmann-La Roche Ltd. · Switzerland
- Thermo Fisher Scientific Inc. (U.S.)
- Hologic, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- OmicronLab · Mexico
- QIAGEN N.V. · Netherlands
- Danaher Corporation (U.S.)
- Abbott Laboratories (U.S)
- Agilent Technologies, Inc. (U.S.)
Frequently asked questions
This market study covers the market sizes & forecasts of the molecular diagnostics market in Latin America based on offering, test type, technology, application, end user, and geography. This market study also provides the value analysis of various segments and subsegments of the Latin America molecular diagnostics market at country levels.
Cite this report
Meticulous Research. (2025). Latin America Molecular Diagnostics Market - Opportunity Analysis and Industry Forecasts (2025-2032) (Report No. MRHC - 1041076). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/latin-america-molecular-diagnostics-market-5759